Resultados de Búsqueda
For guidance on using temozolomide for treating newly diagnosed grade III glioma, see the NICE technology appraisal guidance on carmustine implants and temozolomide for the treatment of newly ...
NICE
National Institute for Health and Clinical Excellence (NICE)
After surgery, offer sequential radiotherapy and 4 to 6 cycles of PCV chemotherapy to people who have: a Karnofsky performance status of 70 or more and a newly diagnosed grade III glioma with 1p/19q codeletion (anaplastic oligodendroglioma). Agree with the person with the anaplastic oligodendroglioma the order of PCV chemotherapy and radiotherapy after discussing the potential advantages and disadvantages of each option with them. After surgery, offer radiotherapy followed by up to 12 cycles ...
ver más ... 2018Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults. It is ...
NICE
National Institute for Health and Clinical Excellence (NICE)
People with untreated ALK-positive advanced NSCLC are usually offered crizotinib. The main evidence for alectinib comes from an ongoing clinical trial. This suggests that alectinib is more effective than crizotinib in delaying disease progression, including in the central nervous system. There is not enough evidence to tell how long alectinib prolongs life compared with crizotinib. There is uncertainty about how treatments after disease progression affect people's quality and length of life. ...
ver más ... 2018Pembrolizumab is recommended as an option for untreated PD‑L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD‑L1 (with at least a 50% tumour proportion ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Only if pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and the company provides pembrolizumab according to the commercial access agreement. People with untreated metastatic PD‑L1-positive NSCLC are usually offered platinum-based chemotherapy (docetaxel, gemcitabine, paclitaxel, vinorelbine or pemetrexed, with a platinum-based drug). Clinical trial evidence shows that pembrolizumab increases the length of time people live by ...
ver más ... 2018Crizotinib is recommended for use within the Cancer Drugs Fund as an option for treating ROS1‑positive advanced non-small-cell lung cancer (NSCLC) in adults, only if the conditions in the managed ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with crizotinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
ver más ... 2018Atezolizumab is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with atezolizumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Treatments for NSCLC after chemotherapy include docetaxel alone, pembrolizumab (for tumours expressing the PD‑L1 protein) and ...
ver más ... 2018